Omez

# Omez ## Overview - **Classification**: Proton Pump Inhibitor (PPI) - **Mechanism**: Irreversibly blocks the H+/K+-ATPase (proton pump) in gastric parietal cells, suppressing gastric acid secretion. ## Primary Indications 1. **Gastroesophageal Reflux Disease (GERD)** - Symptomatic relief and healing. 2. **Erosive Esophagitis (EE)** - Healing and long-term management. 3. **Duodenal/Gastric Ulcers** - Treatment and prevention of recurrence. 4. **_H. pylori_ Eradication** - Part of multi-drug regimens. 5. **Zollinger-Ellison Syndrome (ZES)** - Management of hypersecretory conditions. ## Adult Dosing ### Standard Dosing **Gastroesophageal Reflux Disease (GERD)** - **Dose**: **20 mg** - **Frequency**: Once daily - **Route**: Oral - **Duration**: 4-8 weeks; maintenance **10-20 mg** daily. **Erosive Esophagitis (EE)** - **Dose**: **20 mg** - **Frequency**: Once daily - **Route**: Oral - **Duration**: 4-8 weeks; maintenance **20 mg** daily. **_H. pylori_ Eradication (Triple Therapy)** - **Dose**: **20 mg** - **Frequency**: Twice daily (BID) - **Route**: Oral - **Duration**: 10-14 days (with clarithromycin and amoxicillin/metronidazole). **Zollinger-Ellison Syndrome (ZES)** - **Dose**: Initial **60 mg** - **Frequency**: Once daily - **Route**: Oral - **Special Considerations**: Doses >80 mg/day usually divided. ### Dose Adjustments - **Renal Impairment**: No dose adjustment generally needed. - **Hepatic Impairment**: Max **20 mg** daily for patients with severe hepatic impairment (Child-Pugh Class C). - **Elderly Patients**: No specific dose adjustment, but monitor for long-term adverse effects. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: **0.7-1.5 mg/kg** - **Frequency**: Once daily - **Maximum**: **20 mg** daily - **Special Notes**: Off-label use, consider alternative agents or lower doses. Use liquid formulation if available. ### Infants (1-12 months) - **Dose**: **0.7-1.5 mg/kg** - **Frequency**: Once daily - **Maximum**: **20 mg** daily - **Special Notes**: Off-label use. Consider dividing doses for higher range if tolerated. ### Children (1-12 years) - **GERD/EE (≥1 year, ≥5 kg)**: - 5 to <10 kg: **5 mg** once daily - 10 to <20 kg: **10 mg** once daily - ≥20 kg: **20 mg** once daily - **Frequency**: Once daily - **Maximum**: **20 mg** daily for GERD/EE - **Special Notes**: Approved for GERD/EE. Use oral suspension/granules for ease of administration. ### Adolescents (13-18 years) - **Dose**: Generally follows adult dosing guidelines. - **Frequency**: Once daily - **Maximum**: **20 mg** daily for GERD, up to **40 mg** daily for EE. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to omeprazole, substituted benzimidazoles, or any component. - **Absolute**: Concomitant use with **rilpivirine-containing products**. - **Relative**: Gastric malignancy should be ruled out before initiating. ### Common Adverse Effects - **Very Common (>10%)**: Headache - **Common (1-10%)**: Nausea, diarrhea, abdominal pain, constipation, flatulence. - **Serious but Rare**: _Clostridioides difficile_ associated diarrhea, acute interstitial nephritis, bone fractures (long-term), hypomagnesemia (long-term), B12 deficiency (long-term), fundic gland polyps (long-term). ### Key Drug Interactions - **Clopidogrel**: Reduced antiplatelet effect; avoid concomitant use or use alternative PPIs (e.g., pantoprazole). - **CYP2C19 Substrates (e.g., Warfarin, Diazepam, Phenytoin)**: Omeprazole is a strong CYP2C19 inhibitor; may increase levels of these drugs. Monitor INR for warfarin. - **Drugs Requiring Acidic Environment (e.g., Atazanavir, Nelfinavir, Iron Salts, Ketoconazole)**: Reduced absorption and efficacy; avoid or monitor closely. - **Tacrolimus**: Increased tacrolimus levels; monitor drug levels. ## Monitoring & Follow-up - **Before Treatment**: Rule out gastric malignancy in adult patients with persistent symptoms. - **During Treatment**: Symptom resolution, monitor for signs of _C. difficile_ infection (persistent diarrhea). - **Clinical Signs**: Watch for unexplained weight loss, dysphagia, or GI bleeding. With long-term use (>1 year), monitor serum magnesium, vitamin B12 levels. ## Clinical Pearls - 💡 **Timing**: Take **30-60 minutes before the first meal** of the day for best efficacy. - 💡 **Administration**: Do **NOT crush or chew** delayed-release capsules. For patients unable to swallow, sprinkle granules on applesauce. - 💡 **Long-term Use**: Discuss risks of bone fracture, _C. difficile_, hypomagnesemia, and vitamin B12 deficiency with patients on prolonged therapy. - 💡 **Step-Down**: Reassess need for continued PPI therapy periodically; consider step-down to H2RA or on-demand therapy if appropriate. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.